EirGenix Bundle
What is the history of EirGenix?
Founded in 2012, EirGenix aimed to speed up the creation and market entry of new biological medicines. Initially, the company focused on providing top-notch, affordable CDMO services and developing its own biosimilar products.
This dual approach of outsourced manufacturing and proprietary product development has been central to its strategy. The global biologics CDMO market is expanding rapidly, with projections indicating growth from USD 21.3 billion in 2024 to USD 24.37 billion in 2025, and further to USD 42.33 billion by 2029.
EirGenix has established itself as Taiwan's largest CDMO for mammalian and microbial-derived biologics, offering a full suite of services. The company supports clients from cell line development through to cGMP manufacturing. As of July 2025, EirGenix is in the process of IPO registration, highlighting its significant growth. Understanding the competitive landscape is crucial, and an EirGenix Porter's Five Forces Analysis can provide valuable insights.
What is the EirGenix Founding Story?
The EirGenix company history began with its official founding on December 21, 2012, in New Taipei, Taiwan. This marked the start of a significant venture aimed at addressing the growing need for high-quality biopharmaceutical services and affordable biosimilar treatments.
EirGenix Founding Story
EirGenix Inc. was established through a strategic joint venture in March 2013, uniting EirGenix, Inc., Formosa Laboratories, Inc., and the Development Center for Biotechnology (DCB). This collaboration was instrumental in EirGenix's early development, granting them operational rights to DCB's cGMP biopharmaceutical pilot plant and access to a skilled team.
- EirGenix company founding date: December 21, 2012.
- Key partners in the founding joint venture: Formosa Laboratories, Inc., and the Development Center for Biotechnology (DCB).
- Founder, Chairman, and President: Dr. Lee-Cheng Liu, bringing over 30 years of industry experience.
- Initial funding secured: USD 15.1 million in a Seed Round in April 2013.
- EirGenix's dual business model: CDMO services and proprietary biosimilar development.
- First major product in development: EG12014, a biosimilar to trastuzumab.
- Cultural influence: Taiwan's established expertise in small molecule API manufacturing fostered confidence in its biopharmaceutical potential.
Dr. Lee-Cheng Liu, a seasoned professional with over 30 years of experience in product, process development, and manufacturing across the biotech, pharmaceutical, and specialty chemical sectors, spearheaded the EirGenix company journey and evolution. His vision was to create a contract development and manufacturing organization (CDMO) that could compete with global leaders in terms of quality, such as Boehringer Ingelheim or Lonza, while simultaneously pursuing the development of its own biosimilar products. This ambition was a driving force behind the EirGenix background and its initial strategic decisions. The company's initial business model was designed to be comprehensive, encompassing both contract development and manufacturing operations (CDMO) and the development of proprietary products, with a particular focus on biosimilars. This dual approach allowed EirGenix to leverage its capabilities across different market segments. The EirGenix company mission and vision history clearly pointed towards becoming a significant player in both service provision and product innovation within the biopharmaceutical industry. The EirGenix company founding was also influenced by the broader context of Taiwan's robust history in small molecule API manufacturing, which created a strong belief in the nation's capacity to excel in the more complex field of biopharmaceutical CDMO services. This belief was supported by the existing expertise and infrastructure that could be adapted and enhanced. The EirGenix company overview highlights this strategic positioning from its inception. The EirGenix company impact on the pharmaceutical industry began with these foundational steps, aiming to provide both essential manufacturing services and innovative therapeutic alternatives. The EirGenix company early years and growth were predicated on this solid strategic foundation and the vision of its founder. The EirGenix company evolution from startup to established business was set in motion by these initial, well-defined objectives and the strong collaborative partnerships formed. The Marketing Strategy of EirGenix would later build upon these early achievements and market positioning.
EirGenix SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of EirGenix?
The EirGenix company history showcases a rapid ascent in the contract development and manufacturing organization (CDMO) sector. From its founding, the company focused on leveraging existing infrastructure and expertise to build a strong operational base.
Early Foundation and Operational Strength
EirGenix quickly established its foothold in the CDMO market in March 2013, utilizing inherited cGMP pilot plants for mammalian and microbial systems. The company's early success was attributed to efficient operations and a skilled technical and management team, leading to remarkable sales growth and breaking even by 2016.
Significant Expansion in Protein Drug Production
A major milestone was the January 2019 launch of a new protein drug production plant in Zhubei, Taiwan. This facility, equipped with advanced single-use bioreactors, significantly enhanced EirGenix's capacity for late-stage development and commercial production.
Revenue Growth and Capital Investment
By 2019, EirGenix experienced substantial revenue growth, reportedly increasing 35 times since its founding, with revenue projected to reach NT$500 million. This growth was supported by significant capital raises, totaling USD 480 million, from prominent investors to fuel strategic planning and pipeline expansion.
Regulatory Approvals and Market Trust
The company's facilities have secured approvals from major international regulatory bodies, including the USFDA, Japan PMDA (in 2020), Australia TGA, and EU EMA. These accreditations have been crucial in fostering client trust and driving business growth, contributing to its Target Market of EirGenix.
EirGenix PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in EirGenix history?
EirGenix has marked significant progress in its contract development and manufacturing organization (CDMO) services and proprietary product development. A key achievement is the advancement of EG12014, a biosimilar for breast cancer treatment, which has completed Phase III trials and is awaiting regulatory approval, demonstrating bioequivalence to a leading Herceptin® product. The company is the first in Taiwan to complete EU biosimilar clinical trials for EG12014, which is already approved in Taiwan and the EU. US FDA approval is anticipated by the end of 2024, with an on-site inspection planned for late 2024. A higher-dosage version is slated for a 2025 global launch. This journey reflects the EirGenix company journey and evolution.
| Year | Milestone |
|---|---|
| 2024 | Submitted Phase III clinical trial applications for EG1206A to regulatory authorities. |
| 2024 | Anticipated US FDA approval for EG12014 by year-end, following an expected on-site inspection. |
| 2025 | Planned global launch of a higher-dosage version of EG12014. |
EirGenix offers a full spectrum of services, from developing proprietary CHO-K1 cell lines to cGMP manufacturing for mammalian and microbial systems. The company is also expanding into cell and gene therapy, focusing on DNA plasmid development and large-scale production. Its pipeline includes EG1206A (Pertuzumab biosimilar in Phase I), EG13074 (new formulation in preclinical), TSY0110/EG12043 (antibody-drug conjugate in preclinical), EG12021 (Bevacizumab biosimilar in preclinical), and EG62054 (another biosimilar in preclinical). The company also produces COVID-19 antigen rapid tests.
Biosimilar Development
EirGenix is advancing EG12014, a biosimilar to trastuzumab, through Phase III trials and regulatory filings, aiming for US FDA approval by the end of 2024.
Cell Line Development
The company utilizes proprietary CHO-K1 cell lines for comprehensive services, including cell line development and process optimization.
Cell and Gene Therapy Investment
EirGenix is actively investing in cell and gene therapy, offering development and large-scale production of DNA plasmids.
Diverse Product Pipeline
The company's pipeline includes multiple biosimilars and novel formulations in various stages of development, showcasing its broad R&D capabilities.
cGMP Manufacturing
EirGenix provides cGMP manufacturing for mammalian and microbial systems, ensuring high-quality production standards.
COVID-19 Antigen Tests
The company also manufactures COVID-19 antigen rapid tests, demonstrating its adaptability to market needs.
EirGenix faces challenges common to the biologics industry, including high development costs and complex manufacturing processes. Regulatory hurdles, which vary by region, also present obstacles. The company's 2023 revenue saw a decline due to deferred milestone payments, facility re-validation, and a dip in CDMO market demand. This highlights the inherent risks in the EirGenix company operations.
High Development Costs
The development of biologics is inherently expensive, requiring substantial investment in research, clinical trials, and manufacturing.
Complex Manufacturing
Biologics manufacturing involves intricate processes that demand rigorous quality control and specialized expertise.
Regulatory Hurdles
Navigating diverse and region-specific regulatory requirements is a significant challenge for global market access.
Market Demand Fluctuations
The CDMO market can experience fluctuations in demand, impacting revenue streams as seen with deferred milestone payments.
Facility Re-validation
Periodic facility expansions and equipment re-validation can temporarily affect operational capacity and financial reporting.
Maintaining Competitive Edge
Despite challenges, the company focuses on quality and its vertically integrated model to maintain competitiveness and control costs.
EirGenix Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for EirGenix?
The EirGenix company history is a testament to strategic growth and innovation in the biopharmaceutical sector. Founded on December 21, 2012, in New Taipei, Taiwan, the company quickly established key partnerships and secured crucial funding to fuel its development. This EirGenix company overview highlights its journey from inception to its current standing.
| Year | Key Event |
|---|---|
| 2012 | EirGenix Inc. was founded in New Taipei, Taiwan. |
| 2013 | Signed a joint venture agreement with Formosa Laboratories, Inc. and Development Center for Biotechnology (DCB), obtaining rights to operate DCB's cGMP biopharmaceutical pilot plant facility and integrating its personnel. |
| 2013 | Completed a Seed Round funding of USD 15.1 million. |
| 2016 | Secured Early Stage VC funding and achieved break-even point in sales. |
| 2019 | Opened a new protein drug production plant in Zhubei, Taiwan, and completed IPO registration. |
| 2020 | Xizhi facility received Japan PMDA approval. |
| 2021 | Completed a private placement of NTD 5.0325 billion with significant investors. |
| 2022 | Engaged in a Later Stage VC deal with TFBS Bioscience. |
| 2023 | Expected completion of an additional production line at the Zhubei facility, increasing capacity. |
| 2024 | Reported 108.1% year-on-year growth in proposal value for collaborations, estimated at over USD 1 billion. |
| 2024 | Anticipated US FDA approval for EG12014 (Trastuzumab biosimilar). |
| 2025 | Plans to launch a higher-dosage version of EG12014 globally. |
Market Expansion and Capacity Growth
The company is set to benefit from the expanding biologics CDMO market, projected to reach USD 92.37 billion by 2034. This growth is supported by strategic plans to increase facility capacity, including a large-scale manufacturing facility with a total bioreactor capacity of 150,000 liters.
Product Portfolio Enhancement
Future development includes expanding the product portfolio with more biosimilar drug products and diversifying CDMO offerings into cell and gene therapy. This aligns with the company's vision to accelerate new biological medicines to market.
Strategic Collaborations and Licensing
The company aims to accelerate development through in-licensing and collaboration agreements. The second-generation breast cancer biosimilar, Pertuzumab (EG1206A), is expected to finalize licensing agreements by the end of 2024, with projected total licensing revenue exceeding USD 70 million.
Commitment to Accessibility and Affordability
EirGenix remains committed to providing high-quality and cost-effective CDMO services and biologics. The company's mission is to enhance global well-being by making high-quality biopharmaceutical drugs affordable and accessible, a core tenet of its Growth Strategy of EirGenix.
EirGenix Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Competitive Landscape of EirGenix Company?
- What is Growth Strategy and Future Prospects of EirGenix Company?
- How Does EirGenix Company Work?
- What is Sales and Marketing Strategy of EirGenix Company?
- What are Mission Vision & Core Values of EirGenix Company?
- Who Owns EirGenix Company?
- What is Customer Demographics and Target Market of EirGenix Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.